Status:
COMPLETED
Characterization and Functionality of Calcium Channels Cav1.4 of Th17 Lymphocytes in Human With Psoriasis
Lead Sponsor:
Pierre Fabre Dermo Cosmetique
Collaborating Sponsors:
Centre National de la Recherche Scientifique, France
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Psoriasis
Eligibility:
MALE
18-65 years
Phase:
NA
Brief Summary
It's clearly known that lymphocyte activation in particular Th17 response, plays a major role in the development of plaque psoriasis. New therapies targeting this pathway are showing great clinical ef...
Detailed Description
* Evaluate the expression of Cav1.4 calcium channels by Th17 lymphocytes from plaque psoriasis. * To assess: * The role of Cav1.4 channels on the activation of Th17 lymphocytes * The transcriptom...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Group 1 : Subject with plaque psoriasis (diagnosis confirmed by dermatologist) with a plaque IGA score ≥ 3
- Group 2 : Subject with atopic dermatitis according to the UK Working party criteria with an IGA plaque score ≥3
- Exlusion Criteria:
- Group 1 : Other chronic inflammatory dermatosis than plaque psoriasis at the sites to be sampled
- Group 2 : Other chronic inflammatory dermatosis than Atopic Dermatitis at the sites to be sampled
- For both groups: Ongoing treatment with calcium channel blockers
- For both groups: Any current topical treatment on the biopsied or systemic plaque for psoriasis or AD (including phototherapy)
Exclusion
Key Trial Info
Start Date :
October 25 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 13 2017
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04459780
Start Date
October 25 2016
End Date
November 13 2017
Last Update
July 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Dermatologie - Hôpital Larrey
Toulouse, France, 31400